Pipeline
Jenrin’s PR CB1 receptor blocker program has identified several high affinity leads. Development activities have primarily focused on JD5037 that recently completed its IND-enabling studies. JD5037 has been shown to have little or no brain presence by in vitro, tissue distribution, in vivo receptor occupancy and behavioral studies. Efficacy has been shown in a variety of in vivo assays demonstrating the compound’s potential as a therapeutic for diabetes, liver and kidney diseases as well as obesity. The back-up candidates that have been identified and are awaiting further pharmacological characterization. A patent estate around the lead compound and analogs has been established with broad international coverage.